Zentalis Pharmaceuticals Inc. (ZNTL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZNTL Stock Price Chart Interactive Chart >
ZNTL Price/Volume Stats
| Current price | $23.60 | 52-week high | $59.65 |
| Prev. close | $23.50 | 52-week low | $17.33 |
| Day low | $23.44 | Volume | 666,528 |
| Day high | $24.52 | Avg. volume | 600,066 |
| 50-day MA | $21.05 | Dividend yield | N/A |
| 200-day MA | $24.17 | Market Cap | 1.35B |
Zentalis Pharmaceuticals Inc. (ZNTL) Company Bio
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
Latest ZNTL News From Around the Web
Below are the latest news stories about ZENTALIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ZNTL as an investment opportunity.
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on January 3, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 30,625 shares of the Company’s common stoc |
Can Zentalis Pharmaceuticals, Inc. (ZNTL) Climb 170% to Reach the Level Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 170.4% in Zentalis Pharmaceuticals, Inc. (ZNTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
These 4 “Strong Buy” Stocks are on Analysts’ RadarsGerman economist Karl Otto Pohl once famously compared inflation with toothpaste — "Once it's out, you can hardly get it back in again," he had said. However, October's inflation reading gave us some hope, having cooled to 7.7% year-over-year. Nonetheless, this is far from the Federal Reserve's target inflation rate of 2%-3%, and the economy still has a long way to go. In such an environment, stocks that Wall Street analysts are rooting for are worth keeping an eye on. Here are four "Strong Buy" stocks to consider—Duolingo (NASDAQ:DUOL), Jazz Pharmaceuticals (NASDAQ:JAZZ), Trade Desk (NASDAQ:TTD), and Zentalis Pharmaceuticals (NASDAQ:ZNTL). Duolingo (DUOL) Mobile language learning platform provider Duolingo recently posted revenue and earnings beats. |
Analysts Offer Insights on Healthcare Companies: Sol-Gel Technologies (SLGL), Zentalis Pharmaceuticals (ZNTL) and Oncology Institute, Inc. (TOI)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sol-Gel Technologies (SLGL – Research Report), Zentalis Pharmaceuticals (ZNTL – Research Report) and Oncology Institute, Inc. (TOI – Research Report) with bullish sentiments. Sol-Gel Technologies (SLGL) Raymond James analyst Elliot Wilbur maintained a Buy rating on Sol-Gel Technologies today and set a price target of $13.00. The company's shares closed last Friday at $4.74, close to its 52-week low of $3.94. According to TipRanks. |
ZNTL Price Returns
| 1-mo | 17.18% |
| 3-mo | -3.67% |
| 6-mo | -23.13% |
| 1-year | -58.65% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 17.18% |
| 2022 | -76.04% |
| 2021 | 61.84% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...